{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:24:20Z","timestamp":1792643060328,"version":"4.5.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17465"],"award-info":[{"award-number":["20K17465"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Breakthrough candidemia (BrC) is a significant problem in immunocompromised patients, particularly those with hematological disorders. To assess the characteristics of BrC in patients with hematologic disease treated with novel antifungal agents, we collected clinical and microbiological information on said patients from 2009 to 2020 in our institution. Forty cases were identified, of which 29 (72.5%) received hematopoietic stem cell transplant (HSCT)-related therapy. At BrC onset, the most administered class of antifungal agents were echinocandins, administered to 70% of patients. Candida guilliermondii complex was the most frequently isolated species (32.5%), followed by C. parapsilosis (30%). These two isolates were echinocandin-susceptible in vitro but had naturally occurring FKS gene polymorphisms that reduced echinocandin susceptibility. Frequent isolation of these echinocandin-reduced-susceptible strains in BrC may be associated with the widespread use of echinocandins. In this study, the 30-day crude mortality rate in the group receiving HSCT-related therapy was significantly higher than in the group not receiving it (55.2% versus 18.2%, P\u00a0=\u00a0.0297). Most patients affected by C. guilliermondii complex BrC (92.3%) received HSCT-related therapy and had a 30-day mortality rate of 53.8%; despite treatment administration, 3 of 13 patients had persistent candidemia. Based on our results, C. guilliermondii complex BrC is a potentially fatal condition in patients receiving HSCT-related therapy with echinocandin administration.<\/jats:p>","DOI":"10.1093\/mmy\/myad056","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T13:52:44Z","timestamp":1686577964000},"source":"Crossref","is-referenced-by-count":10,"title":["Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009\u20132020"],"prefix":"10.1093","volume":"61","author":[{"given":"Ruriko","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-230X","authenticated-orcid":false,"given":"Yoshihiro","family":"Eriguchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Nagasaki","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"},{"name":"Department of Infectious Disease, National Hospital Organization Kyushu Medical Center , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-5723","authenticated-orcid":false,"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Shimono","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science , Fukuoka , Japan"},{"name":"Center for the Study of Global Infection, Kyushu University Hospital , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"2023063008171823700_bib1","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023063008171823700_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"key":"2023063008171823700_bib3","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023063008171823700_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"2023063008171823700_bib6","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023063008171823700_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy","volume":"28","author":"Rotstein","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"2023063008171823700_bib9","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/cncr.10610","article-title":"Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials","volume":"94","author":"Bow","year":"2002","journal-title":"Cancer"},{"key":"2023063008171823700_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/clinids\/24.2.275","article-title":"Breakthrough candidemia in neutropenic patients","volume":"24","author":"Nucci","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(95)00010-0","article-title":"The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance","volume":"100","author":"Hong","year":"1996","journal-title":"Am J Med"},{"key":"2023063008171823700_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic infections in patients treated with immunotherapy for cancer","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2023063008171823700_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4137\/BMI.S22430","article-title":"Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors","volume":"10s3","author":"Reinwald","year":"2015","journal-title":"Biomarker Insights"},{"key":"2023063008171823700_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof7020156","article-title":"Invasive fungal infections after anti-CD19 chimeric\u00a0antigen receptor-modified T-cell therapy: state of the evidence and future directions","volume":"7","author":"Garner","year":"2021","journal-title":"J Fungi"},{"key":"2023063008171823700_bib15","doi-asserted-by":"crossref","first-page":"e01791","DOI":"10.1128\/AAC.01791-16","article-title":"Clinical and microbiological characteristics of breakthrough candidemia in allogeneic hematopoietic stem cell transplant recipients in a Japanese hospital","volume":"61","author":"Kimura","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/mmy\/myx038","article-title":"Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents","volume":"56","author":"Kim","year":"2018","journal-title":"Med Mycol"},{"key":"2023063008171823700_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cmi.2015.09.029","article-title":"Breakthrough candidaemia in the era of broad-spectrum antifungal therapies","volume":"22","author":"Cuervo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2023063008171823700_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10096-002-0697-1","article-title":"Risk factors for breakthrough candidemia","volume":"21","author":"Nucci","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023063008171823700_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jinf.2017.12.018","article-title":"Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study","volume":"76","author":"Orasch","year":"2018","journal-title":"J Infect"},{"key":"2023063008171823700_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/mmy\/myx077","article-title":"Breakthrough candidemia after the introduction of broad spectrum antifungal agents: a 5-year retrospective study","volume":"56","author":"Breda","year":"2018","journal-title":"Med Mycol"},{"key":"2023063008171823700_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1086\/320757","article-title":"Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia","volume":"32","author":"Uzun","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib22","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1093\/cid\/ciaa1523","article-title":"Clinical characteristics and outcomes of breakthrough candidemia in 71 hematologic malignancy patients and\/or allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study from China, 2011\u20132018","volume":"71","author":"Chen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2023063008171823700_bib25","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1128\/AAC.00836-10","article-title":"FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance","volume":"54","author":"Zimbeck","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1006290","article-title":"Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally","volume":"13","author":"Chowdhary","year":"2017","journal-title":"PLoS Pathog"},{"key":"2023063008171823700_bib27","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib28","first-page":"219","article-title":"Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: fifteen years of interpretation and assessment","volume":"58","author":"Fraser","year":"2020","journal-title":"Med Mycol"},{"key":"2023063008171823700_bib29","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997-2016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023063008171823700_bib30","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.00865-06","article-title":"Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program","volume":"44","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2023063008171823700_bib31","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/JCM.00356-06","article-title":"Candida guilliermondii fungemia in patients with hematologic malignancies","volume":"44","author":"Girmenia","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2023063008171823700_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3324\/haematol.11149","article-title":"Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy","volume":"93","author":"Kabbara","year":"2008","journal-title":"Haematologica"},{"key":"2023063008171823700_bib33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/IDR.S156633","article-title":"Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan","volume":"11","author":"Hirano","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2023063008171823700_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijantimicag.2014.05.015","article-title":"Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints","volume":"44","author":"Gamaletsou","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023063008171823700_bib35","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/mmy\/myu066","article-title":"Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia","volume":"52","author":"Abe","year":"2014","journal-title":"Med Mycol"},{"key":"2023063008171823700_bib36","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1086\/432939","article-title":"Candida glabrata fungemia: experience in a tertiary care center","volume":"41","author":"Malani","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"2023063008171823700_bib38","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JCM.00937-12","article-title":"Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2023063008171823700_bib39","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.00088-08","article-title":"Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing","volume":"52","author":"Desnos-Ollivier","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023063008171823700_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J Infect Dis"},{"key":"2023063008171823700_bib42","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1128\/AAC.00349-06","article-title":"Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility","volume":"50","author":"Katiyar","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib43","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.00262-08","article-title":"A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility","volume":"52","author":"Garcia-Effron","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib44","doi-asserted-by":"crossref","first-page":"e02644","DOI":"10.1128\/AAC.02644-16","article-title":"Molecular confirmation of the relationship between Candida guilliermondii Fks1p naturally occurring amino acid substitutions and its intrinsic reduced echinocandin susceptibility","volume":"61","author":"Dudiuk","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib45","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.3314\/mmj.18.004","article-title":"Role of FKS gene in the susceptibility of pathogenic fungi to echinocandins","volume":"59","author":"Hori","year":"2018","journal-title":"Med Mycol J"},{"key":"2023063008171823700_bib46","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1128\/JCM.00938-16","article-title":"Identification and antifungal susceptibility profile of Candida guilliermondii and Candida fermentati from a multicenter study in China","volume":"54","author":"Cheng","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2023063008171823700_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1439-0507.2010.01960.x","article-title":"What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast","volume":"54","author":"Savini","year":"2011","journal-title":"Mycoses"},{"key":"2023063008171823700_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/mmy\/myaa044","article-title":"A case-series of bloodstream infections caused by the Meyerozyma guilliermondii species complex at a reference center of oncology in Brazil","volume":"59","author":"Chaves","year":"2021","journal-title":"Med Mycol"},{"key":"2023063008171823700_bib49","doi-asserted-by":"crossref","first-page":"myac071","DOI":"10.1093\/mmy\/myac071","article-title":"Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010\u20132019: a retrospectiveobservational study based on national surveillance data","volume":"60","author":"Kajihara","year":"2022","journal-title":"Med Mycol"},{"key":"2023063008171823700_bib50","doi-asserted-by":"crossref","first-page":"e00099","DOI":"10.1128\/AAC.00099-17","article-title":"Candida guilliermondii complex is characterized by high antifungal resistance but low mortality in 22 cases of candidemia","volume":"61","author":"Marcos-Zambrano","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib51","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/513663","article-title":"The epidemiology of hematogenous candidiasis caused by different Candida species","volume":"24","author":"Abi-Said","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2023063008171823700_bib52","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/cncr.23466","article-title":"The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"2023063008171823700_bib53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0002-9343(01)01130-5","article-title":"The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer","volume":"112","author":"Bodey","year":"2002","journal-title":"Am J Med"},{"key":"2023063008171823700_bib54","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.37.9.1847","article-title":"Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients","volume":"37","author":"Wingard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2023063008171823700_bib55","doi-asserted-by":"crossref","first-page":"491.e1","DOI":"10.1016\/j.cmi.2014.12.027","article-title":"Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain","volume":"21","author":"Puig-Asensio","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2023063008171823700_bib56","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1703252","article-title":"Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome","volume":"28","author":"Safdar","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2023063008171823700_bib57","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"2023063008171823700_bib58","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/JCM.02390-09","article-title":"Breakthrough invasive candidiasis in patients on micafungin","volume":"48","author":"Pfeiffer","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2023063008171823700_bib59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-023-05856-5","article-title":"Structural and mechanistic insights into fungal beta-1,3-glucan synthase FKS1","volume":"616","author":"Hu","year":"2023","journal-title":"Nature"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad056\/50599426\/myad056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/6\/myad056\/50744002\/myad056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/6\/myad056\/50744002\/myad056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T08:20:45Z","timestamp":1688113245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad056\/7197442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad056","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,6]]},"article-number":"myad056"}}